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Introduction: The aim of the study was to compare the results of two human papillomavirus (HPV) 
diagnostic techniques: human papillomavirus deoxyribonucleic acid (HPV DNA) testing and human 
papillomavirus E6/E7 messenger ribonucleic acid (HPV E6/E7 mRNA) testing in women with squamous 
cell abnormalities of the uterine cervix.
Material and Methods: Comparative prospective study, conducted in the period from January 2016 to 
June 2017 of 128 sexually active women, age groups of 20 to 59 years (40.50 ± 10.85) with squamous 
cell abnormalities on the cervical cytology. All patients were subject to: HPV DNA testing, HPV E6/E7 
mRNA testing and colposcopic cervical biopsy with endocervical curettage for histopathologycal analysis. 
HPV DNA testing was done using multiplex polymerase chain reaction (PCR) and reverse hybridization 
methods. HPV E6/E7 mRNA testing was done using real-time PCR method.
Results: Data analysis showed an association between the results of HPV DNA testing and HPV E6/E7 
mRNA testing (p˂0.0001). The concordance between the results of both tests was moderate (55.47%). 
The results show that HPV E6/E7 mRNA testing had a higer specificity 88.89% and positive predictive 
value (PPV) 93.59% for HSIL + invasive squamous cell carcinoma compared to HPV DNA testing that 
had specificity of 55.56% and PPV 84.61%, respectively.
Conclusion: The results of our study suggested that HPV E6/E7 mRNA testing is more specific and has a 
higher positive predictive value than HPV DNA testing and that viral oncoproteins E6 and E7 are superior 
biomarkers for the detection of high-risk HPV-associated squamous intraepithelial lesions of the uterine cervix.
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COMPARISON BETWEEN HPV DNA TESTING  
AND HPV E6/E7 MRNA TESTING IN WOMEN  
WITH SQUAMOUS CELL ABNORMALITIES OF THE UTERINE CERVIX
Squamous cell carcinoma of the uterine cer-
vix is the most common histological subtype of cer-
vical cancer. About 90% of cases of cervical cancer 
are squamous carcinoma, 10% are adenocarcinomas 
and a small percentage of other subtypes [1]. The 
occurrence of cervical carcinoma is preceded by 
various forms of intraepithelial lesions involving a 
series of progressive morphological changes from 
productive human papillomavirus (HPV) infec-
tion-mild dysplasia to in situ carcinoma [2]. This 
phase is generally asymptomatic and occurs over 
a period of 10 to 20 years [3]. 
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The six main clinical applications of human 
papillomavirus deoxyribonucleic acid (HPV DNA) 
testing are: triage of women with ASC-US (atypical 
squamous cells of undetermined significance) and 
LSIL (low-grade squamous intraepithelial lesion); 
monitoring of women with abnormal screening re-
sults that are negative for colposcopy and/or biopsy; 
predicting a therapeutic outcome after treatment of 
an intraepithelial lesion; as a primary screening test; 
obtaining information on the existence of certain 
HPV genotypes and determining the prevalence of 
certain genotypes of HPV at regional, national or 
global levels [4,5].
 HPV DNA tests only detect HPV infection. 
Based on these tests, it can not be concluded whether 
it is a transient (80%) or a long-term/persistent (20%) 
HPV infection [6]. Human papillomavirus E6/E7 
messenger ribonucleic acid (HPV E6/E7 mRNA) 
tests determine the oncogenic activity of the virus 
and represent a good clinical biomarker for the pre-
diction and detection of the direct risk of developing 
cervical cancer [7].
The five most important advantages of HPV 
E6/E7 mRNA tests over HPV DNA tests are: they 
are more specific, non-invasive tests; have a greater 
medical predictive value (greater prognostic sig-
nificance) in relation to HPV DNA detection tests 
[8]; correlate better with cytology and histology [9]; 
directly detect the expression level of oncogen HPV 
E6 and E7 (mRNA) and at the same time detect, 
differentiate and type high-risk HPV-genotypes -16, 
-18, -31, -33 and -45 [10]. 
The aim of the study is to compare the HPV 
DNA and HPV E6 E7 mRNA test results in wom-
en with squamous cell abnormalities of the uterine 
cervix, to prove that HPV E6/ E7 mRNA testing has 
greater specificity and greater positive predictive 
value than HPV DNA testing, to prove that viral on-
coproteins E6 and E7 are predictive biomarkers for 
the detection of high-risk HPV-associated squamous 
intraepithelial cervical lesions.
MATERIAL AND METHODS
Comparative prospective study, conducted in 
the period from January 2016 to June 2017 at the 
University Clinic of Gynecology and Obstetrics and 
Radiotherapy and Oncology in Skopje and the Insti-
tute of Public Health of the Republic of Macedonia 
in Skopje of 128 sexually active women, age groups 
of 20 to 59 years (40.50 ± 10.85) with squamous cell 
abnormalities on the cervical cytology, who came 
to their annual gynaecological exam at University 
Clinic for Gynaecology and Obstetrics in Skopje. 
The study did not include: pregnant women, women 
with previous cervical surgery (conization, carbon 
dioxide laser vaporization and total hysterectomy) 
and women with previous abnormal cytological and 
histopathological findings of the uterine cervix.
In all patients was done: HPV DNA testing, 
HPV E6/E7 mRNA testing and colposcopic cervical 
biopsy with endocervical curettage for histopatho-
logical analysis.
CYTOPATHOLOGICAL ANALYSIS. All sam-
ples for cytology were taken using the Thin Prep PAP 
smear cytology and were analyzed in the Laboratory 
of the University Clinic of Gynecology and Obstet-
rics in Skopje by a doctor-cytopathologist. Cytolog-
ical results were classified according to the revised 
Bethesda classification [11,12], such as: ASC-US, 
Atypical Squamous Cells of Undetermined Signifi-
cance; ASC-H, Atypical Squamous Cells cannot ex-
clude a high-grade squamous intraepithelial lesion; 
LSIL, Low-grade Squamous Intraepithelial Lesion 
(CIN 1, Cervical Intraepithelial Neoplasia grade 1); 
HSIL, High-grade Squamous Intraepithelial Lesion 
(CIN 2, Cervical Intraepithelial Lesion grade 2; CIN 
3, Cervical Intraepithelial Neoplasia grade 3; CIS, 
Carcinoma In Situ) and invasive squamous cell car-
cinoma.
HISTOPATHOLOGICAL ANALYSIS. Sam-
ples for histopathological analysis were taken to the 
University Clinic of Gynecology and Obstetrics in 
Skopje and were analyzed at the University Clinic 
of Oncology and Radiotherapy in Skopje, Depart-
ment of Histopathology and Clinical Cytology, by 
an experienced expert in pathohistology. According 
to the morphology of the bioptic samples, the cervi-
cal findings were characterized as: normal finding 
(nonspecific cervicitis); LSIL (mild dysplasia, flat 
condyloma, cervicitis chronica virosa); HSIL (mod-
erate and severe dysplasia, in situ squamous cell car-
cinoma) and invasive squamous cell carcinoma [13].
HPV DNA TESTING. The analysis of the sam-
ples from the cervical swabs, detection and HPV 
typing were made at the University Clinic of Gynae-
cology and Obstetrics in Skopje, in the Laboratory 
for HPV typing. The first step in HPV testing was 
the isolation of DNA from the collected cells of the 
cervical swabs. For isolation of DNA series of three 
paraffin cuts were prepared. Cuts were incubated in 
1 ml of xylene, 5 minutes at 55℃, and centrifuged 
at 10 000 G for five minutes at room temperature. 
The same procedure was repeated two more times. 
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After careful removal of the remains of xylene, the 
samples were briefly incubated twice in 1 ml of 100% 
ethanol, and centrifuged for 5 minutes at room tem-
perature. After the removal of ethanol, short drying 
followed in air and incubation overnight in buffer 
with freshly added proteinase K at 55℃. The sec-
ond step was the detection of DNA in HPV by us-
ing polymerase chain reaction (PCR). To verify the 
quality and integrity of the isolated DNA, actually 
of a present inhibitor, for each sample a reaction of 
multiplication of the specific primers for beta glo-
bin PC04 and GH20 was first made. Three pairs of 
primers were used, common to a larger number of 
HPV types: degenerate primers My09/My11 and 
CPI/CPII G and Gp5/6+. The samples were carried 
through all reactions with primers specific to high-
risk and low-risk HPV genotypes. The third step was 
genotyping by using reverse hybridization. It is a 
method that is based on the hybridization of specific 
DNA probes that are immobilized on nitrocellulose 
or nylon tapes. It is a set of primers (SPF 10) with 
aim-propagation of the L1 gene on the viral DNA. 
The product of amplification with SPF primers is 
the size of 65 bp, and allows detection of 25 new 
genotypes. Denatured biotinylated PCR products are 
hybridized with specific oligonucleotide probes that 
are immobilized as parallel lines on membrane strips. 
After hybridization and washing with streptavidin, 
alkaline phosphatase is added, which binds to the 
biotinylated hybrids formed previously. Incubation 
with BCIP (5-bromo-4-chloro-3-indolyl-phosphate)/
NBT (nitro blue tetrazolium) chromogen gives pur-
ple precipitate and the results are interpreted visually.
HPV E6/E7 mRNA TESTING. All samples 
for HPV E6/E7 mRNA testing were taken from the 
cervix, using a “blue” cytobrush at the Universi-
ty Clinic of Gynaecology and Obstetrics in Skopje 
and were analyzed in the Laboratory of the Institute 
of Public Health of the Republic of Macedonia in 
Skopje by a doctor-virologist. We used tests that 
use the Real-Time PCR method. The results were 
analyzed and shown qualitatively, whether there is 
the presence or absence of HPV E6/E7 oncoproteins 
[14]. HPV E6/E7 mRNA testing was done in three 
steps. The first step was the isolation of viral RNA 
using the commercial test of the Nuclisense nucleid 
acid isolation test (Biomerieux) by following the 
manufacturer’s recommendations. The socond step 
was the detection of viral RNA. The detection meth-
od is based on the application of NASBA (Nucleic 
Acid Sequence Based Assay) technology and the 
Easy Q Nuclisens platform was used. Detection was 
performed using the PreTect HPV Proofer test, Nor 
Chip AS, Norway. The test enables qualitative mo-
lecular detection of mRNA from oncogens E6 and 
E7 to the 5 most common HPV genotypes: -16, -18, 
-31, -33, -45. The third step of HPV E6/E7 mRNA 
was software processing and displaying the results.
STATISTICAL ANALYSIS. Data were analysed 
by a specific software for data-bases (Excel). Sta-
tistical analysis of the established statistical series 
was made with the statistical program SPSS (Sta-
tistical Package for Social Sciences), version 23.0. 
The structure of numerical signs was analysed by 
determining the measures of central tendency (arith-
metical mean) and measures of dispersion (standard 
deviation). Analysis of the relationship (the existence 
of association) between two sets of attribute varia-
bles was performed using the Chi-square test. Analy-
sis of the relationships (the existence of correlation) 
between two sets of  numerical variables was per-
formed using the regression analysis and coefficient 
of linear correlation. The concordance among the 
DNA and RNA tests results was evaluated by using 
Cohen’s kappa statistic: k value of ˂0.20 indicated 
poor concordance, k value from 0.21 to 0.40 indi-
cated sufficient concordance, k value from 0.41 to 
0.60 indicated moderate concordance, k value from 
0.61 to 0.80 indicated good concordance and k value 
˃0.80 indicated very good concordance. The sensi-
tivities, specificities and PPVs for the HPV DNA 
and RNA assays were estimated by comparison with 
the cytological and histological findings. Statistical 
significance was defined as a p value <0.05.
RESULTS
Of the 128 examinate patients aged from 20 
to 59 years (40.50 ± 10.85): 28 (21.87%) were aged 
20-29; 38 (29.69%) 30-39 years; 30 (23.44%) 40-49 
years and 32 (25.00%) were aged 50-59 years.
Cytopathologically, there were: 13 (10.16%) 
ASC-US cases, 7 (5.47%) ASC-H cases, 31 (24.22%) 
LSIL cases, 56 (43.75%) HSIL cases and 21 (16.40%) 
invasive squamous cell carcinomas. Histopatholog-
ically, there were: 9 (7.03%) non-neoplastic lesions, 
41 (32.03%) LSIL cases, 54 (42.19%) HSIL cases 
and 24 (18.75%) invasive squamous cell carcinomas.
HPV DNA infection was detected in 75.00% 
(96/128) of the patients studied. Data analysis 
showed an increase in HPV infection, along with 
an increase in the histopathological grade of cervi-
cal lesion. The lowest percentage was observed in 
LSIL 63.41% (26/41), with an increase up to 83.33% 
(45/54) in HSIL and 87.50% (21/24) in invasive 
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squamous cell carcinoma (chi-square test=7.0506, 
p=0.029443, p˂0.05) (Table 1). The data analysis 
showed an association between the presence of HPV 
DNA infection and the occurrence of squamous 
cell abnormalities of the uterine cervix (chi-square 
test=4.8204, p=0.028125, p <0.05). 
HPV E6/E7 mRNA infection was detected in 
60.94% (78/128) of examined patients. Data analysis 
showed an increase in HPV E6/E7 mRNA infection, 
along with an increase in the histopathological grade 
of cervical lesion. The lowest percentage was found 
in LSIL 9.76% (4/41), followed by 92.59% (50/54) 
in HSIL and 95.83% (23/24) in invasive squamous 
cell carcinoma of the uterine cervix (chi-square 
test=82.7796, p˂0.00001, p˂0.05) (Table 1). Data 
analysis showed an association between the presence 
of viral oncoproteins E6 and E7 and the incidence 
of squamous cell abnormalities of the uterine cervix 
(chi square test=10.0967, p=0.001485, p<0.05).
Hystopathological 
diagnosis
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21 (87.50 3 (12.50) 23 (95.83) 1 (4.17) 21 (87.50) 0.125 0.467 -0.132 – 
1.000
Total (n=128) 96 (75.00) 32 (25.00) 78 (60.94) 50 (39.06) 71 (55.47) ˂0.001 0.439 0.282 – 
0.596
Table 1. Comparison between HPV DNA testing and HPV E6/E7 mRNA testing in relation to histopathological diagnosis
Legend: n, number; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial 
lesion; CI, confidence interval 
Out of a total of 128 patients, 71 (55.47%) 
were HPV positive for both tests. Data analy-
sis showed an association between the results 
of HPV DNA testing and HPV E6/E7 mRNA 
testing (chi-square test=27.3504, p˂0.0001, 
p˂0.05). The concordance between the results of 
both tests was moderate (55.47%; kappa=0.439; 
95%CI: 0.282-0.596). HPV DNA testing was su-
perior to the detection of LSIL (63.41%; 26/41 
versus 9.76%; 4/41), while HPV E6/E7 mRNA 
testing was superior to the detection of HSIL 
(92.60%; 50/54 versus 83.33%; 45/54) and in-
vasive squamous cell carcinoma of the uterine 
cervix (95.83%, 23/24 versus 87.50%; 21/24) 
(Table 1). 
Data analysis from both tests showed: good 
concordance between the results of patients with 
severe dysplasia (82.61%; kappa=0.623) and in 
situ squamous cell carcinoma (87.50%; 0.636), 
moderate concordance between those with mod-
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erate dysplasia (80.00%; kappa=0.467), suf-
ficient concordance between those with mild 
dysplasia (15.79%; kappa=0.240) and normal 
histopathological findings on the uterine cervix 
(11.11%; kappa=0.444) and invasive squamous 
cell carcinoma of the uterine cervix (87.50%; 
kappa=0.270) and poor concordance between 
the results of patients with cervicitis chronica vi-
rosa (5.00%; kappa=0.055) and flat condyloma 
(0%; kappa=0.000) (Table 1).
Table 2. Sensitivity and specificity of HPV DNA 























Legend: HPV, human papillomavirus; DNA, deoxy-
ribonucleic acid; mRNA, messenger ribonucleic acid; CI, 
confidence interval
Table 3. Positive predictive value of HPV DNA and 
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Legend: HPV, human papillomavirus; DNA, deoxyribonu-
cleic acid; mRNA, messenger ribonucleic acid; LSIL, low-
grade squamous intraepithelial lesion; HSIL, high-grade 
squamous intraepithelial lesion
The accuracy of HPVDNA testing was 
75.78%, while the accuracy of HPV E6/E7 
mRNA testing was 66.41%. The results show 
that HPV E6/E7 mRNA testing had a higer 
specificity 88.89% and positive predictive value 
(PPV) 93.59% for HSIL + invasive squamous 
cell carcinoma compared to HPV DNA testing 
that had specificity of 55.56% and PPV 84.61%, 
respectively (Tables 2 and 3).
HPV 
genotype






Presence Absence Presence Absence
n (%) n (%) n (%) n (%) n (%)
16 45 (35.16) 83 (64.84) 42 (32.81) 86 (67.19) 40 (31.25) ˂0.0001 0.878 0.791-0.966
18 18 (14.06) 110 (85.94) 10 (7.81) 118 (92.19) 9 (7.03) ˂0.0001 0.603 0.384-0.822
31 15 (11.72) 113 (88.28) 15 (11.72) 113 (88.28) 14 (10.94) ˂0.0001 0.924 0.821-1.000
33 8 (6.25) 120 (93.75) 7 (5.47) 121 (94.53) 6 (4.69) ˂0.0001 0.788 0.555-1.000
45 13 (10.16) 115 (89.84) 9 (7.03) 119 (92.97) 9 (7.03) ˂0.0001 0.802 0.614-0.989
16/18 13 (10.16) 115 (89.84) 7 (5.47) 121 (94.53) 7 (5.47) ˂0.0001 0.677 0.438-0.916
Legend: HPV, human papillomavirus; DNA, deoxyribonucleic acid; 
mRNA, messenger ribonucleic acid; CI, confidence interval
Table 4. Distribution of HPV genotypes detected with HPV DNA and HPV E6/E7 mRNA tests in 128 patients
Data analysis from both tests showed: very 
good concordance between the results of patients 
with HPV-16 and HPV-31, good concordance 
between those with HPV-33, HPV-45 and HPV-
16/18 and a moderate concordance between the 
results of patients with HPV-18 (Table 4).
DISCUSSION
Persistent high-risk HPV infections are the 
most common risk factors for the occurrence of 
squamous cell cervical abnormalities. 75% of 
the sexually active population, in the course of 
their lives, was in contact with one or more HPV 
genotypes [15]. In this study, HPV DNA infection 
was detected in 75% of patients. This relatively 
high percentage of HPV DNA infection in 
patients with squamous cell abnormalities of the 
uterine cervix  corresponds to some previously 
published studies [16,17]. According to the 
known prevalence of HPV genotypes in invasive 
cervical cancer, more than 80% of potential cases 
can be detected by the PreTect HPV-Proofer 
assay. According to the International Agency for 
Research on Cancer analysis of 3 085 invasive 
cervical carcinoma, the five most common HPV 
56 Drage Dabeski et al.
genotypes were with decreasing frequency, 
HPV-16, -18, -45, -31, and -33. These genotypes 
were found in 82.9% of the cases [18]. 
In our study, high-risk HPV E6/E7 mRNA 
infection was detected in 60.94% of patients. This 
relatively high percentage of high-risk HPV E6/
E7 mRNA infection in patients with squamous 
cell cervical abnormalities corresponds to some 
previously published studies; The study of 
Fontecha et al., compiled in the period from 2007 
to 2014, showed HPV E6/E7 mRNA positivity in 
68.29% of women, who for the first time were 
HPV E6/E7 mRNA tested [19], the study by 
Oliveira et al. from 2013, worked on 554 women, 
detected the expression of viral oncoproteins E6 
and E7 in 55.10% of women surveyed [20], in a 
study by Cattani et al. from 2009, worked on 400 
HPV DNA positive women, 61.20% of women 
were HPV E6/E7 mRNA positive [21], study by 
Tuney et al. from 2017, showed an expression 
of viral oncoproteins E6 and E7 in 55.60% of 
women with abnormal cervical cytological 
findings [22].
Data analysis from our study showed an 
association between the results of HPV DNA 
testing and HPV E6/E7 mRNA testing (p˂0.0001). 
An association between the results of HPV DNA 
testing and HPV E6/E7 mRNA testing was also 
detected in the study of Doganov A. et al. from 
2012 [23]. The concordance between the results 
of both tests was moderate (55.47%). The study 
of Trope et al. from 2009, worked on 643 women 
with HSIL-finding on the PAP test, showed 
concordance of 63.80% between the results of 
HPV DNA and HPV E6/E7 mRNA tests [24]. In 
the study of Spathis et al. from 2012, worked on 1 
173 women at the University Clinic in Ioannina, 
a concordance of 71.60% was found between 
the HPV DNA and HPV E6/E7 mRNA tests 
[25]. The study of Salimovic-Besic from 2013, 
conducted on 105 women with abnormal cervical 
cytological findings, showed a concordance of 
56.00% between the HPV DNA test and HPV 
E6/E7 mRNA test, with low HPV E6/E7 mRNA 
positivity in women with cytological findings of 
ASC-US on the PAP test [26].
The results of our study showed that HPV 
E6/E7 mRNA testing was more specific (88.89%) 
and higher positive predictive value (93.59%) of 
HPV DNA testing. A greater specificity (50.00%) 
and greater positive predictive value (62.00%) 
of HPV E6/E7 mRNA testing was shown by the 
study of Duvlis S. et al. from 2015 conducted 
on a screening group of 413 Macedonian women 
[27], as well as some other previously published 
studies; the study of Cattani et al. since 2009, 
it has been developed for 180 women, showed 
more specificity (72.70%) of HPV E6/E7 mRNA 
testing than HPV DNA testing (56.20%) [21]. 
In the study of Munkhdelger et al. from 2014, 
conducted on 188 women with squamous 
intraepithelial cervical lesion, HPV E6/E7 
mRNA testing was more specific than HPV DNA 
testing (85.00% versus 40.83%) [28].
CONCLUSION
The results of our study have suggested that 
HPV E6/E7 mRNA testing is more specific and 
has a higher positive predictive value than HPV 
DNA testing and that viral oncoproteins E6 and 
E7 are superior biomarkers for the detection of 
high-risk HPV-associated squamous intraepithe-
lial lesions of the uterine cervix.
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Резиме
СПОРЕДБА МЕЃУ ХПВ ДНК-ТЕСТИРАЊЕТО И ХПВ Е6/Е7 ИРНК-ТЕСТИРАЊЕТО  
КАЈ ЖЕНИ СО СКВАМОЗНИ КЛЕТОЧНИ АБНОРМАЛНОСТИ НА ГРЛОТО НА МАТКАТА
Драге Дабески1, Сотирија Дувлис3, Нели Башеска2, Весна Антовска1, Марјан Стојовски1, 
Милка Трајанова1, Горан Димитров1, Ана Дабески1, Надица Гурева-Ѓоргиевска1
1 Универзитетска клиника за гинекологија и акушерство, Медицински факултет, Универзитет 
„Свети Кирил и Методиј“, Скопје, Република Македонија
2 Универзитетска клиника за радиотерапија и онкологија, Медицински факултет, Универзитет 
„Свети Кирил и Методиј“, Скопје, Република Македонија
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Кирил и Методиј“, Скопје, Република Македонија
Вовед: Целта на студијата беше да ги споредиме резултатите од двете дијагностички техни-
ки за хуман папилома вирус (ХПВ): тестирањето хуман папилома вирус дезоксирибонуклеинска 
киселина (ХПВ ДНК) и тестирање хуман папилома вирус Е6/Е7 информативна рибонуклеинска 
киселина (ХПВ Е6/Е7 иРНК) кај жените со сквамозни клеточни абнормалности на грлото на матката.
Материјал и методи: Компаративната проспективна студија беше спроведена во периодот 
од јануари 2016 до јуни 2017 година, на 128 сексуално активни жени, на возраст од 20 до 59 го-
дини (40,50 ± 10,85) со цитолошки сквамозни клеточни абнормалност на грлото на матката. Кај 
сите пациентки направивме: тестирање ХПВ ДНК, тестирање ХПВ Е6/Е7 иРНК и колпоскопска 
цервикална биопсија со ендоцервикална киретажа за хистопатолошка анализа. Тестирањето ХПВ 
ДНК беше направено со помош на методите: мултипна полимераза верижна реакција и реверзна 
хибридизација. Тестирањето ХПВ Е6/Е7 иРНК беше направено со помош на полимераза верижна 
реакција во реално време.
Резултати: Анализата на податоците покажа асоцијација меѓу резултатите од тестирањето 
ХПВ ДНК и тестирањето ХПВ Е6/Е7 иРНК (p ˂ 0,0001). Конкордантноста меѓу резултатите од 
двете тестирања беше умерена (55,47 %). Резултатите покажаа дека тестирањето ХПВ Е6/Е7 иРНК 
има поголема специфичност 88,89 % и поголема позитивна предиктивна вредност (ППВ) 93,59 % 
кај HSIL + инвазивен сквамозен карцином во споредба со тестирањето ХПВ ДНК, кое има специ-
фичност 55,56 % и ППВ 84,61 %.
Заклучок: Резултатите од нашата студија потврдија дека тестирањето ХПВ Е6/Е7 иРНК е со 
поголема специфичност и поголема позитивна предиктивна вредност од тестирањето ХПВ ДНК и 
дека вирусните онкопротеини Е6 и Е7 се супериорни биомаркери за детекција на високоризичните 
ХПВ-асоцирани сквамозни интраепителни лезии на грлото на матката.
Клучни зборови: ХПВ, ДНК, иРНК, Е6/Е7, грло на матка
